Compare Lufax Holding Ltd (LU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs ResMed Inc. — how do they compare? Lufax Holding Ltd trades at $0.99 (market cap $982.89M), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 32.4× Lufax Holding Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and ResMed Inc. for 51 Days on average.
| LU | RMD | |
|---|---|---|
Market Cap | $982.89M | $31.89B |
Volume | 3,323,384 | 618,314 |
Sector | Financials | Health |
52-Week High | $3.93 | $277.88 |
52-Week Low | $0.95 | $182.82 |
Typical Hold Time | 13 Days | 51 Days |
Enterprise Value | $58.81B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.98, down 0.11% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and ROE. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026. Analyst consensus remains positive with 69% buy ratings, though earnings have consistently missed expectations.
LU presents a deep value opportunity with P/S of 0.25 and P/B of 0.07, but faces significant execution risks amid declining revenue and persistent losses. The company's strong parent backing from Ping An and improving operational cash flow provide some stability, but regulatory headwinds in China's consumer lending market remain a concern for sustained recovery.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
